New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer
Transl Androl Urol
.
2020 Apr;9(2):837-839.
doi: 10.21037/tau.2020.03.24.
Authors
Ching-Yu Lin
1
2
,
Chih-Pin Chuu
1
3
Affiliations
1
Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan, Miaoli.
2
PhD Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University, Taipei.
3
PhD Program for Aging and Graduate Institute of Basic Medical Science, China Medical University, Taichung.
PMID:
32420195
PMCID:
PMC7215030
DOI:
10.21037/tau.2020.03.24
No abstract available
Publication types
Editorial
Comment